Aprea Therapeutics, Inc. APRE
Set alert
0.49 USD +0.01 +1.32%
At close · Nov 2
0.48 -0.01 -1.28%
After hours · Nov 2, 4:00 PM ET
0.488 Day range 0.5199
0.41 52-week range 1.49
- YTD
- -42.44%
- 1 year
- -64.93%
- Open
- 0.50
- Prev close
- 0.4846
- Mkt cap
- 6.18M
- Vol
- 89.16K
- Avg vol
- 310.11K
- EPS
- -0.95
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.488
- High
- 0.5199
- Forward P/E
- -3.08
- Beta
- 1.74
- Short ratio
- 0.55
- Inst. own
- 43.85%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 12, 2024
- 50-d avg
- 3.48
- 200-d avg
- 4.17
- 1y target
- 15.67
2Y chart
Events in this range
- Nov 7, 2024Earnings: -0.64; estimate -0.75; surprise 14.67%
- Nov 18, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Dec 17, 2024Rating: HC Wainwright & Co. · Buy → Buy
Signals (74)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 26, 2026 | 1 week ago |
| RSI: Oversold | Oct 8, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 1, 2026 | 1 month ago |
| SMA: Bearish | Sep 9, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 9, 2026 | 1 month ago |
| SMA: Bullish | Sep 8, 2026 | 1 month ago |
| SMA: Bearish | Sep 2, 2026 | 2 months ago |
| SMA: Bullish | Sep 1, 2026 | 2 months ago |
| SMA: Bearish | Aug 31, 2026 | 2 months ago |
| SMA: Bullish | Aug 25, 2026 | 2 months ago |
| RSI: Overbought | Aug 25, 2026 | 2 months ago |
| SMA: Bullish | Aug 24, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 6, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 9, 2026 | 3 months ago |
| MACD: Buy Signal | Jun 22, 2026 | 4 months ago |
| SMA: Bearish | Jun 1, 2026 | 5 months ago |
| MACD: Sell Signal | May 29, 2026 | 5 months ago |
| MACD: Buy Signal | May 22, 2026 | 5 months ago |
| SMA: Bullish | May 20, 2026 | 5 months ago |
| SMA: Bearish | May 19, 2026 | 5 months ago |
Newest 20 of 74.
Key statistics
- Market cap
- 17.07M
- Enterprise value
- -5.20M
- Trailing P/E
- 0.00
- Forward P/E
- -3.08
- PEG ratio
- 0.00
- Price / sales
- 13.38
- Price / book
- 0.69
- EPS (TTM)
- -2.80
- Beta
- 1.74
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 1.28M
- Revenue growth
- 124.90%
- Free cash flow
- -9.36M
- Total cash
- 28.69M
- Total debt
- 0
- Return on equity
- -50.11%
- Shares outstanding
- 5.43M
- Short % of float
- 0.38%
- 50-day average
- 3.48
- 200-day average
- 4.17
Analyst view
Consensus: buy
Buy
Price target (mean) 15.67 +3090.8% upside
Now 0.491
- Target (low)
- 11.00
- Target (mean)
- 15.67
- Target (high)
- 20.00
Ratings (0m) 3 3 buy · 0 hold · 0 sell
- Strong buy2
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 12, 2024
Expected Aug 12, 2024. Consensus EPS estimate -0.57.
Financials — quick view
APRE Revenue — quarterly 0
APRE Net income — quarterly -3.59M
APRE EPS — quarterly -0.07
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.75 | -0.64 | +0.11 | +14.67% |
| Aug 12, 2024 | Jun 1, 2024 | -0.64 | -0.58 | +0.06 | +9.38% |
| Aug 12, 2024 | Jun 1, 2024 | -0.64 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | -0.78 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | -0.78 | -0.67 | +0.11 | +14.10% |
| Mar 26, 2024 | Dec 1, 2023 | -0.56 | -0.92 | -0.36 | -64.29% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 17, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 18, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 24, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 13, 2024 | Wedbush | reit | Outperform | Outperform |
| Aug 12, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 24, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Aprea Therapeutics, Inc.
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- aprea.com
News
- Aprea Therapeutics to Host Pre-ESMO Virtual Panel on the State of WEE1 Inhibition in Precision Oncology
- Ladenburg Thalmann Initiates Coverage On Aprea Therapeutics with Buy Rating, Announces Price Target of $2
- 12 Health Care Stocks Moving In Thursday's After-Market Session
- Aprea Therapeutics to Present at October Conferences
- Aprea Therapeutics Announces Abstract Featuring Updated Interim Results From The Ongoing Phase 1 ACESOT-1051 Study Of Its WEE1 Inhibitor APR-1051 In Patients With Advanced Solid Tumors Has Been Accepted For Oral Presentation At The Symposium On Molecular Targets And Cancer Therapeutics
- Aprea Therapeutics to Present Updated Interim Phase 1 Data on WEE1 Inhibitor APR-1051 in an Oral Presentation at 38th EORTC-NCI-AACR Symposium
- Aprea Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
- Aprea Therapeutics Expands Current Patent Portfolio
- Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs
- 12 Health Care Stocks Moving In Thursday's Intraday Session
Your note
Sign in to keep a note on APRE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DUEY MARC | Director | Sale | Oct 17, 2024 | 234,253 |
| GILAD OREN PH.D. | Chief Executive Officer | Purchase | Oct 22, 2024 | 335,195 |
| GRISSINGER MICHAEL J. | Director | Stock Award(Grant) | Jun 19, 2024 | 1,844 |
| HAMILL JOHN P | Chief Financial Officer | Purchase | Oct 10, 2024 | 19,368 |
| HENNEMAN JOHN BELL III | Director | Stock Award(Grant) | Jun 19, 2024 | 9,184 |
| MIRZA NADEEM Q. | Officer | Stock Award(Grant) | Apr 30, 2024 | 6,730 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AIGH Capital Management LLC | 9.92% | 539,300 | 1.69M | Sep 29, 2024 |
| Sio Capital Management, LLC | 5.09% | 276,603 | 868.53K | Sep 29, 2024 |
| Sphera Funds Management Ltd. | 4.97% | 270,000 | 847.80K | Sep 29, 2024 |
| Nantahala Capital Management, LLC | 3.79% | 205,760 | 646.09K | Sep 29, 2024 |
| Vanguard Group Inc | 3.20% | 173,842 | 545.86K | Sep 29, 2024 |
| Stonepine Capital Management, LLC | 2.52% | 137,174 | 430.73K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.67% | 145,280 | 456.18K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.53% | 28,562 | 89.68K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.47% | 25,275 | 79.36K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.13% | 7,197 | 22.60K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.11% | 5,963 | 18.72K | Oct 30, 2024 |
| Dimensional ETF Tr-Dimensional U.S. Targeted Value ETF | 0.09% | 5,083 | 15.96K | Jul 30, 2024 |